MedTrace Logo

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NCT05544929 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2026-01-06

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Cutaneous Melanoma
  • Carcinoma, Renal Cell
  • Carcinoma, Ovarian Epithelial
  • Nasopharyngeal Carcinoma
  • Carcinoma, Thymic
  • Anal Cancer
  • Mesothelioma
  • Esophagogastric Cancer
  • High Microsatellite Instability Colorectal Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Triple Negative Breast Neoplasms

Interventions

DRUG

KFA115

Immunomodulatory agent

DRUG

pembrolizumab

Anti-PD-1 antibody

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-26
Primary Completion
2027-09-01
Completion
2027-09-01
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • France
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • Singapore
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544929 on ClinicalTrials.gov